Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

0.9078 -0.0776 (-7.87%)
Streaming Delayed Price Updated: 3:13 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with... 
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
Via Benzinga
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. 
Via Benzinga
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
Exposures Glyphosate
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.